Skip to content

Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer

Compare Gastric Acid Suppression of Esomeprazole by Oral or Intravenous Administration - A Randomized Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00471029
Acronym
NPH
Enrollment
20
Registered
2007-05-09
Start date
2005-09-30
Completion date
2007-09-30
Last updated
2007-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peptic Ulcer

Keywords

pH study, peptic ulcer, proton pump inhibitor

Brief summary

The purpose of this study is to compare the gastric acid suppression profile among different regimen (Oral Vs Intravenous)of administration of proton pump inhibitor - Esomeprazole by 24hours intragastric pH monitoring.

Detailed description

Peptic ulcer bleeding is a common medical emergency. Although primary hemostasis can be achieved by endoscopic hemostasis in more than 90% of cases, rebleeding during the first 72 hours is still common. The use of secretory inhibitors in ulcer bleeding had theoretical benefit in preventing rebleeding. In vitro, platelet aggregation and disaggregation, coagulation and fibrinolysis are strongly dependent on intra-gastric pH. When pH falls below 6.0, platelet disaggregation takes place and below 4.0, fibrin clots dissolved. Pharmacological studies have clearly shown that primed proton-pump inhibitor (PPI) infusion is superior to H2-receptor blocler (H2B) injection or infusion in maintaining high intra-gastric pH. Randomized trials had demonstrated the advantage of adjuvant use of intravenous or oral PPI in reducing rebleeding as compared to placebo. However, as Asian subjects generally have lower body weight and acid output than Caucasians, the dosage of PPI required for prevent rebleeding may be different. Lin et al had demonstrated that in an Asian population study, in order to show a significant clinical effect in prevent peptic ulcer rebleeding after endoscopic hemostasis, at least a 30% difference in duration in maintaining an intragastric pH \>6 must be achieved. As there is substantial cost implication of routine use of high dose intravenous PPI infusion (80mg bolus + 8mg/hour for 72 hours, cost \ HKD$1100) against high dose oral esomeprazole (40mg BD for 3 days, cost \ HKD$60), the optimal doses and routes of administration of PPI in achieving effective acid suppression is needed to be clearly defined. Protocol: Patients presented with bleeding peptic ulcers (melena, hememtesis) will undergo endoscopy. If clean base peptic ulcer which dos not require endoscopic treatment is diagnosed, consented patients will randomly allocated into 2 groups using sealed envelopes containing a therapeutic option derived from a randomized table. 1. Esomeprazole infusion (80mg bolus then 8mg/hour) (192mg/d) 2. Esomeprazole Tablet oral 40mg 12 hourly (80mg/d) A pH electrode with internal reference (Synetic) was inserted transnasally and positioned 10cm below the cardia. It was calibrated before and after the pH recording with standard buffer solutions of pH 7.00 and pH 1.00. The electrode was connected to a data logger (Mircodigitrapper, Synetic). At the end of 24hours recording, the data were transfer to a personal computer for analysis. Medication will be given after insertion of intra-gastric pH monitor probe. Outcome measures Primary Outcome: total % Time pH \> 6 & 4 Secondary outcome: Median intragastric pH & Time to reach pH 4 and 6

Interventions

DRUGesomeprazole

Sponsors

Pamela Youde Nethersole Eastern Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. Patients with non-bleeding peptic ulcer which do not require endoscopic therapy. 2. Chinese, Age ³18 and \<90 3. Provision of an informed written consent signed by the patient.

Exclusion criteria

1. Treatment of antisecretory drugs during the preceding 4 weeks 2. The present inter-current ulcer complication (gastric outlet obstruction or ulcer perforation) 3. Presence of esophageal / gastric varices 4. aspirin or NSAID user 5. Pregnancy 6. Age \<18 or \>90 7. Moribund patients, patients with severe liver or renal disease 8. Known sensitivity to proton pump inhibitors 9. Previous gastric surgery (except simple patch repair) 10. Patient unable to give written consent 11. Special population, e.g. prisoner, mentally disabled, investigators' student or employees

Design outcomes

Primary

MeasureTime frame
percentage of time intragstric pH > 6 and > 424hours after endoscopy

Secondary

MeasureTime frame
Median intragastric pH24hours after endoscopy
time to attain intragastric pH 4 & 624hours after endoscopy

Countries

China

Contacts

Primary ContactSimon K.H. Wong, MBChB, FRCSEd, FHKAM
wongkhmo@netvigator.com852-25956416

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026